-
Test-retest reliability of DSM-5 substance use symptom checklists used in primary care and mental health care settings.
Hallgren KA, Matson TE, Oliver M, Wang X, Williams EC, Bradley KA. Test-retest reliability of DSM-5 substance use symptom checklists used in primary care and mental health care settings. Drug and Alcohol Dependence 2024;256:111108.
-
PrEP for people who use opioids: A NIDA Clinical Trials Network survey study in southern U.S. cities where HIV incidence is high.
Hatch MA, Laschober TC, Paschen-Wolff M, Ertl MM, Nelson CM, Wright L, Lancaster C, Feaster DJ, Forrest D, Hankey C, Monger M, Fegley JP, Irving R, Young C, Rose J, Spector A, Dresser L, Moran L, Jelstrom E, Tross S. PrEP for people who use opioids: A NIDA Clinical Trials Network survey study in southern U.S. cities where HIV incidence is high. Drug and Alcohol Dependence 2024;257:111133.
-
Medications for opioid use disorder among transition age youth compared to adults 26 or older in rural settings.
Flores JM, Kan E, Mooney LJ, Pham H, Zhu Y, Wolitzky-Taylor K, Hser Y. Medications for opioid use disorder among transition age youth compared to adults 26 or older in rural settings. JAACAP Open 2024;2(4):231-238.
-
Medication treatment for opioid use disorder among rural primary care patients.
Hser Y, Zhu Y, Baldwin L, Mooney LJ, Saxon AJ. Medication treatment for opioid use disorder among rural primary care patients. Journal of Rural Health 2024;40(1):195-199.
-
Research priorities to improve treatment of patients exposed to xylazine-fentanyl: Rapid communication from a National Institute on Drug Abuse Center for the Clinical Trials Network meeting.
Haroz R, Huntley K, Perrone J. Research priorities to improve treatment of patients exposed to xylazine-fentanyl: Rapid communication from a National Institute on Drug Abuse Center for the Clinical Trials Network meeting. Journal of Addiction Medicine 2024;18(1):1-3.
-
Prescription opioid dose reductions and potential adverse events: A multi-site observational cohort study in diverse US health systems.
Metz VE, Ray GT, Palzes V, Binswanger I, Altschuler A, Karmali RN, Ahmedani BK, Andrade SE, Boscarino JA, Clark RE, Haller IV, Hechter RC, Roblin DW, Sanchez K, Bailey SR, McCarty D, Stephens KA, Rosa CL, Rubinstein AL, Campbell CI. Prescription Opioid Dose Reductions and Potential Adverse Events: A Multi-Site Observational Cohort Study in Diverse US Health Systems. Journal of General Internal Medicine 2024;39:1002-1009.
-
Stakeholder perspectives on a telemedicine referral and coordination model to expand medication treatment for opioid use disorder in rural primary care clinics.
Ober AJ, Dopp AR, Clingan SE, Curtis ME, Lin C, Calhoun S, Larkins S, Black M, Hanano M, Osterhage KP, Baldwin L, Saxon AJ, Hichborn EG, Marsch LA, Mooney LJ, Hser Y. Stakeholder perspectives on a telemedicine referral and coordination model to expand medication treatment for opioid use disorder in rural primary care clinics. Journal of Substance Use & Addiction Treatment 2024;156:209194.
-
Individual-level risk prediction of return to use during opioid use disorder treatment.
Luo SX, Feaster DJ, Liu Y, Balise RR, Hu M, Bouzoubaa L, Odom GJ, Brandt L, Pan Y, Hser Y, VanVeldhuisen PC, Castillo F, Calderon AR, Rotrosen J, Saxon AJ, Weiss RD, Wall M, Nunes EV. Individual-level risk prediction of return to use during opioid use disorder treatment. JAMA Psychiatry 2024;81(1):45-56.
-
Efficient and flexible mediation analysis with time-varying mediator, treatments, and confounders.
Díaz I, Williams N, Rudolph KE. Efficient and flexible mediation analysis with time-varying mediator, treatments, and confounders. Journal of Causal Inference 2023;11(1):20220077.
-
Impact of medication-based treatment on health care utilization among individuals with opioid use disorder.
Gopaldas M, Wenzel, K, Campbell ANC, Jalali A, Fishman M, Rotrosen J, Nunes EV, Murphy SM. Impact of medication-based treatment on health care utilization among individuals with opioid use disorder. Psychiatric Services 2023;74(12):1227-1233.